绝经后骨质疏松症的管理
1Department of Medicine, University of Auckland, Auckland, New Zealand.
Endocrine reviews
|February 26, 2026
概括
绝经后的女性面临着显著的骨损失和骨折风险. 本综述涵盖了骨质疏松症,风险评估,生活方式和有效的药物治疗,如双酸盐和骨健康的新药.
科学领域:
- 老年学是一门学科.
- 内分泌学 在内分泌学.
- 整形外科 整形外科 整形外科
背景情况:
- 绝经后的女性经历了骨质的逐渐减少,从而增加骨折的风险.
- 骨质疏松症是一个关键问题,需要准确的骨折风险评估,以有效管理.
- 跌倒是老年人群中骨折的主要原因之一.
研究的目的:
- 审查绝经后的骨损失,骨质疏松症定义和骨折风险估计.
- 讨论改变生活方式和治疗骨质疏松症的药物干预措施.
- 探索当前和新兴的治疗方法来增强骨质量和预防骨折.
主要方法:
- 对绝经后的骨损失,骨质疏松症和骨折风险的文献综述.
- 分析影响骨健康的生活方式因素.
- 对针对骨再吸收和形成的药物剂的评估.
主要成果:
- 生活方式措施 (饮食,运动,戒烟,适度饮酒) 是至关重要的.
- 维生素D缺乏会加剧骨质损失;预防跌倒至关重要.
- 双酸盐 (口服,索莱德酸盐),德诺苏马布,PTH1受体激动剂和罗莫苏马布提供了各种各样的骨折预防益处.
结论:
- 绝经后骨质损失的有效管理需要改变生活方式和向药物治疗.
- 像罗莫苏祖马布这样的新药显示出广泛的抗骨折疗效,而类固醇需要过渡到抗吸收剂.
- 需要进一步的研究来优化顺序治疗策略,以最大限度地减少骨折.
相关概念视频
Bone Remodeling
40.7K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
40.7K
Menopause
5.1K
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
5.1K
Bone Disorders
5.7K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
5.7K
Osteoclasts in Bone Remodeling
4.4K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
4.4K
Role of Vitamins in Maintaining Bone Health
5.8K
The growth and maintenance of bone are regulated by a combination of nutritional factors, including vitamins, such as vitamin A, B12, C, D, and K.
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
5.8K
Atherosclerosis III: Management
516
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
516

